COMP (ng/mL) | Analytical method | Type of analysis | Time point (Days) | Placebo (n = 27) | GC (n = 28) | UC-II (n = 27) | p value (95 % CI) | |||
---|---|---|---|---|---|---|---|---|---|---|
Overalla | GC vs PBO | UC-II vs PBO | UC-II vs GC | |||||||
≥285 | ANCOVA | mITT | 180 | −368 ± 41.7 | −396 ± 40.9 | −574 ± 41.6 | 0.002 | 0.88 (−168 to 112) | 0.002b (−347 to −65) | 0.009c (−317 to −38) |
MMRM | mITT | 180 | −351 ± 44.1 | −398 ± 41.1 | −540 ± 44.2 | 0.006 | 0.71 (−188 to 94) | 0.006b (−330 to −48) | 0.048c (−282 to −1) | |
iAUCd | ITT | 1 to 180 | −1351 ± 212 | −1582 ± 204 | −2384 ± 207 | 0.003 | 0.72 (−934 to 473) | 0.002b (−1741 to −325) | 0.02c (−1498 to −107) | |
(n = 26) | (n = 29) | (n = 26) | ||||||||
<285 | ANCOVA | mITT | 180 | −463 ± 38.8 | −508 ± 36.6 | −526 ± 38.7 | 0.48 | 0.67 (−173 to 82) | 0.49 (−195 to 68) | 0.94 (−145 to 109) |
MMRM | mITT | 180 | −442 ± 38.2 | −493 ± 37.3 | −521 ± 38.1 | 0.34 | 0.60 (−178 to 76) | 0.32 (−208 to 50) | 0.86 (−155 to 100) | |
iAUCe | ITT | 1 to 180 | −1626 ± 185 | −1908 ± 178 | −1902 ± 185 | 0.49 | 0.52 (−896 to 333) | 0.55 (−902 to 350) | 0.99 (−607 to 618) |